Dr Laing joined Lipoxen in March 2002 and has played a leading role in developing the Company’s R&D and Business Development operations and in the establishment of collaborative and licensing deals with the some of the World’s top biotech companies. Dr Laing was a University Lecturer in Immunology until 1994 when he joined Peptide Therapeutics (now Acambis plc) as Director of Research, taking the company through an LSE listing. He has also held key executive positions at Actinova Ltd. (specializing in vaccine development), and Syngenix Ltd. (in the field of CNS drug delivery), as well as acting as a non-executive director of Adjuvantix Ltd. and currently as non-executive Chairman of Activotec Ltd.
Dr Agrawal has extensive experience in the biotech & pharma industry worldwide. He was a founder of the drug delivery company, polyMASC Pharmaceuticals plc, London in 1995. PolyMASC Pharmaceuticals was the first UK biotech company spun-out from a university (Royal Free Hospital, School of Medicine) that was directly listed on AIM, raising approximately $40 million in 1995, and subsequently merged with a NASDAQ-listed company, Valentis Inc (USA) in 1999 to become one of the biggest companies in the delivery of biologics at that time. Dr Agrawal is currently a non-executive Director and Chairman of the remuneration and Vice-Chairman of audit committees of ImmuPharma plc (LSE listed company) and sits on the editorial advisory board of four international biotechnology journals from the USA.
Commenting on the expansion of the management team, Scott Maguire, CEO said “I am very pleased to announce the promotion of Peter and the joining of Ajay and am extremely confident that their knowledge and expertise will further contribute to our continued success.”
“Peter has proven to be a great asset to the Company in transforming its scientific excellence into a focused offering of patent protected delivery solutions that are attractive to licensing partners, while enhancing the Company’s position at the cutting edge in the field of drug delivery.”
“The Board is delighted that Dr Agrawal is joining Lipoxen as his knowledge and broad business development experience will be a valuable addition to the Company. His appointment will play a substantial role in driving the Company forward and help to support the execution of our growth strategy in order to become a leading biopharmaceutical company.”
